22-LUN-129-NP-PMC: CAAA601A42101, A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Tislelizumab in Inducti

Grants and Contracts Details

StatusActive
Effective start/end date8/23/226/12/23

Funding

  • Novartis (domestic): $2.00